Abstract | PURPOSE OF REVIEW:
Hypereosinophilic syndrome is increasingly recognized as a heterogeneous group of disorders, in some cases with precisely defined pathogenesis, which has led to changes in diagnostic approaches and therapeutic strategies. An update on causes and modern therapy is presented here. RECENT FINDINGS: SUMMARY:
|
Authors | Tatjana Peros-Golubicić, Silvana Smojver-Jezek |
Journal | Current opinion in pulmonary medicine
(Curr Opin Pulm Med)
Vol. 13
Issue 5
Pg. 422-7
(Sep 2007)
ISSN: 1070-5287 [Print] United States |
PMID | 17940488
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Benzamides
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- Imatinib Mesylate
- Protein-Tyrosine Kinases
- Receptor, Platelet-Derived Growth Factor alpha
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Benzamides
- Humans
- Hypereosinophilic Syndrome
(diagnosis, drug therapy)
- Imatinib Mesylate
- Piperazines
(pharmacology, therapeutic use)
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Pulmonary Eosinophilia
(diagnosis, drug therapy)
- Pyrimidines
(pharmacology, therapeutic use)
- Receptor, Platelet-Derived Growth Factor alpha
(drug effects, physiology)
|